Life Sciences DNA Podcast

De-Risking Discovery and Improving the Success Rates of Drug Development with AI

Gabi Tarcic, vice president of product for Evogene, sits down with Srivatsan Nagaraja about applying AI to small molecule drug discovery, the cultural and operational changes required for researchers to adopt these tools, and how AI-driven platforms can improve the efficiency of pharma R&D.

Agents of Change: Creating Regulatory Documents with AI

Anita Modi, CEO and founder of Peer AI, joins Srivatsan Nagaraja to discuss the transformative impact of agentic AI on document creation for pharmaceutical companies. She discusses the cultural challenges of integrating AI into a traditionally cautious industry, the need for change management, and why it’s critical to embed human judgment alongside machine intelligence.​

Redefining Biomarkers for Immune-Mediated Disease with AI

Ronel Veksler, co-founder and CEO of PromiseBio, sits down with Amar Drawid to discuss the company’s AI-enabled proteomics platform, and how post-translational modifications of proteins represent a new frontier for precision medicine in autoimmune diseases; and how AI is enabling deep profiling of the epiproteome for better disease subtyping, improved prediction of drug response, and more personalized therapeutic strategies.

Driving Insights from Real World Oncology Data with AI

Aaron Cohen, Head of Research Oncology, Clinical Data for Flatiron Health, sits down with Amar Drawid to discuss Flatiron’s use of large language models to extract and analyze unstructured data from electronic health records. Cohen discusses how AI‑extracted data can replicate human‑curated outcomes across multiple cancer types, paving the way for faster, richer insights to guide both clinical decision‑making and drug development.

Improving Drug Development with Real-World Data

Manfred Stapff, founder and principal of Candid Advisory, sits down with Amar Drawid to discuss the potential of real-world data to accelerate drug development and improve regulatory strategies. He discusses why real-world data can provide insights may miss, shed light on treatment effects once approved, and how it may one day reshape the drug approval process.

Navigating the AI Landscape in Clinical Development

Stephen Pyke, chief clinical data and digital officer at Parexel, sits down with Srivatsan Nagaraja to discuss the adoption of AI technologies in clinical development. He highlights the importance of workflow integration, the challenges of change management, and how to prepare organizations for an AI-driven future.

Transforming Cancer Diagnostics and Care with AI

Mohan Uttarwar, CEO 1Cell.Ai, sits down with Amar Drawid to discuss how his company is transforming cancer diagnostics and care by combining cutting-edge molecular science with advanced AI. He talks about how the company’s single-cell multi-omics platform provides real-time, precision insights, enhances patient selection in clinical trials, and delivers actionable information for oncologists.

Moving Beyond the Hype of AI in Biopharma

Amar Drawid, vice president and global head of data analytics, insights, and AI for BioNTech, sits down with Nagaraja Srivatsan to discuss the evolution, adoption, and challenges of AI in the biopharma sector. He discusses the real-world implementation challenges of generative AI, the iterative process of developing business solutions, and the necessity of effective change management for organizational adoption.